159 related articles for article (PubMed ID: 38702780)
1. Immune checkpoint inhibitors induce acute interstitial nephritis in mice with increased urinary MCP1 and PD-1 glomerular expression.
Martinez Valenzuela L; Gómez-Preciado F; Guiteras J; Antón Pampols P; Gomà M; Fulladosa X; Cruzado JM; Torras J; Draibe J
J Transl Med; 2024 May; 22(1):421. PubMed ID: 38702780
[TBL] [Abstract][Full Text] [Related]
2. Variable Expression of Programmed Cell Death Protein 1-Ligand 1 in Kidneys Independent of Immune Checkpoint Inhibition.
Hakroush S; Kopp SB; Tampe D; Gersmann AK; Korsten P; Zeisberg M; Tampe B
Front Immunol; 2020; 11():624547. PubMed ID: 33552089
[TBL] [Abstract][Full Text] [Related]
3. Anti-PD-1 Immunotherapy May Induce Interstitial Nephritis With Increased Tubular Epithelial Expression of PD-L1.
Cassol C; Satoskar A; Lozanski G; Rovin B; Hebert L; Nadasdy T; Brodsky SV
Kidney Int Rep; 2019 Aug; 4(8):1152-1160. PubMed ID: 31440705
[TBL] [Abstract][Full Text] [Related]
4. Long-term Renal Outcome of Biopsy-proven Acute Tubular Necrosis and Acute Interstitial Nephritis.
Kim H; Jo SK; Ahn SY; Kwon YJ; Lee H; Oh J; Chin HJ; Lim K; Lee J; Yang J; Kim MG; Cho WY; Oh SW
J Korean Med Sci; 2020 Jul; 35(26):e206. PubMed ID: 32627439
[TBL] [Abstract][Full Text] [Related]
5. Programmed death (PD)-1/PD-ligand 1 blockade mediates antiangiogenic effects by tumor-derived CXCL10/11 as a potential predictive biomarker.
Mitsuhashi A; Kondoh K; Horikawa K; Koyama K; Nguyen NT; Afroj T; Yoneda H; Otsuka K; Ogino H; Nokihara H; Shinohara T; Nishioka Y
Cancer Sci; 2021 Dec; 112(12):4853-4866. PubMed ID: 34628702
[TBL] [Abstract][Full Text] [Related]
6. Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy.
Baker ML; Yamamoto Y; Perazella MA; Dizman N; Shirali AC; Hafez N; Weinstein J; Simonov M; Testani JM; Kluger HM; Cantley LG; Parikh CR; Wilson FP; Moledina DG
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35354588
[TBL] [Abstract][Full Text] [Related]
7. Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients.
Shirali AC; Perazella MA; Gettinger S
Am J Kidney Dis; 2016 Aug; 68(2):287-291. PubMed ID: 27113507
[TBL] [Abstract][Full Text] [Related]
8. Programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression in PD-1 inhibitor-associated colitis and its mimics.
Cassol CA; Owen D; Kendra K; Braga JR; Frankel WL; Arnold CA
Histopathology; 2020 Aug; 77(2):240-249. PubMed ID: 32298485
[TBL] [Abstract][Full Text] [Related]
9. Compartmentalization of Intrarenal Programmed Cell Death Protein 1-Ligand 1 and Its Receptor in Kidney Injury Related to Immune Checkpoint Inhibitor Nephrotoxicity.
Tampe D; Kopp SB; Baier E; Hakroush S; Tampe B
Front Med (Lausanne); 2022; 9():902256. PubMed ID: 35755033
[TBL] [Abstract][Full Text] [Related]
10. Urine TNF-α and IL-9 for clinical diagnosis of acute interstitial nephritis.
Moledina DG; Wilson FP; Pober JS; Perazella MA; Singh N; Luciano RL; Obeid W; Lin H; Kuperman M; Moeckel GW; Kashgarian M; Cantley LG; Parikh CR
JCI Insight; 2019 May; 4(10):. PubMed ID: 31092735
[TBL] [Abstract][Full Text] [Related]
11. Ga-67 scintigraphy in the differential diagnosis between acute interstitial nephritis and acute tubular necrosis: an experimental study.
Joaquim AI; Mendes GE; Ribeiro PF; Baptista MA; Burdmann EA
Nephrol Dial Transplant; 2010 Oct; 25(10):3277-82. PubMed ID: 20348147
[TBL] [Abstract][Full Text] [Related]
12. The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
Franzin R; Netti GS; Spadaccino F; Porta C; Gesualdo L; Stallone G; Castellano G; Ranieri E
Front Immunol; 2020; 11():574271. PubMed ID: 33162990
[TBL] [Abstract][Full Text] [Related]
13. Human adipose-derived mesenchymal stem cells prevent type 1 diabetes induced by immune checkpoint blockade.
Kawada-Horitani E; Kita S; Okita T; Nakamura Y; Nishida H; Honma Y; Fukuda S; Tsugawa-Shimizu Y; Kozawa J; Sakaue T; Kawachi Y; Fujishima Y; Nishizawa H; Azuma M; Maeda N; Shimomura I
Diabetologia; 2022 Jul; 65(7):1185-1197. PubMed ID: 35511238
[TBL] [Abstract][Full Text] [Related]
14. Clinical and pathological characteristics of patients with acute kidney injury in Japan in whom kidney biopsy was performed: a cross-sectional analysis of the Japan Renal Biopsy Registry (J‑RBR).
Moniwa N; Tanaka M; Sato H; Shimizu A; Sugiyama H; Yokoyama H; Tsuruya K; Hashiguchi A;
Clin Exp Nephrol; 2022 Oct; 26(10):963-973. PubMed ID: 35595865
[TBL] [Abstract][Full Text] [Related]
15. [Cardiotoxicity of Anti-PD-L1 Antibody and the Effect of Levothyroxine
in Attenuating the Related Mortality in Mice].
Chen Z; Wang M; Gao S; Guo H; Wang G; Zhou G
Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):394-403. PubMed ID: 34157799
[TBL] [Abstract][Full Text] [Related]
16. Study protocol: a prospective single-center study for non-invasive biomonitoring of renal complications in cancer patients treated with immune checkpoint inhibitors.
Baier E; Korsten P; Strauß A; Thoms KM; Overbeck T; Ströbel P; Tampe B
Front Immunol; 2023; 14():1140677. PubMed ID: 37180131
[TBL] [Abstract][Full Text] [Related]
17. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
18. Carboplatin-related acute interstitial nephritis in a patient with pancreatic neuroendocrine tumor.
Asai A; Katsuno T; Yamaguchi M; Iwagaitsu S; Nobata H; Kinashi H; Kitamura H; Banno S; Ito Y
CEN Case Rep; 2020 May; 9(2):114-121. PubMed ID: 31834568
[TBL] [Abstract][Full Text] [Related]
19. Blockade of the PD-1/PD-L1 Immune Checkpoint Pathway Improves Infection Outcomes and Enhances Fungicidal Host Defense in a Murine Model of Invasive Pulmonary Mucormycosis.
Wurster S; Albert ND; Bharadwaj U; Kasembeli MM; Tarrand JJ; Daver N; Kontoyiannis DP
Front Immunol; 2022; 13():838344. PubMed ID: 35251033
[TBL] [Abstract][Full Text] [Related]
20. Incidence and Clinical Features of Immune-Related Acute Kidney Injury in Patients Receiving Programmed Cell Death Ligand-1 Inhibitors.
Seethapathy H; Zhao S; Strohbehn IA; Lee M; Chute DF; Bates H; Molina GE; Zubiri L; Gupta S; Motwani S; Leaf DE; Sullivan RJ; Rahma O; Blumenthal KG; Villani AC; Reynolds KL; Sise ME
Kidney Int Rep; 2020 Oct; 5(10):1700-1705. PubMed ID: 33102962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
